Navigation Links
Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights
Date:8/7/2008

l and accredited investors to place up to $40 million of senior secured convertible notes and on June 9, 2008, the Company placed $20 million of such notes in the initial closing. The notes bear interest at an annual rate of 15% payable at quarterly intervals in stock or cash at the Company's option, and are convertible into shares of Genta common stock at a conversion rate of 100,000 shares of common stock for every $1,000 of principal. In addition, in connection with the placement of the notes, the Company issued a warrant to its private placement agent to purchase 40,000,000 shares of common stock at an exercise price of $0.02 per share and incurred a financing fee of $1.2 million.

On the date that the convertible notes were issued, there were an insufficient number of authorized shares of common stock in order to permit exercise of all of the issued convertible notes. In accordance with EITF 00-19 "Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock" when there are insufficient authorized shares, the conversion obligation for the convertible notes is classified as a liability measured at fair value on the balance sheet. On June 9, 2008, based upon a Black-Scholes valuation model that included a closing price of Genta's common stock of $0.20 per share, a fair value of the conversion feature of $380 million was calculated, and that amount that exceeded the proceeds of the $20 million from the initial closing, $360 million, was expensed. The Company recorded an initial discount of $20 million equal to the face value of the notes.

Similarly, the warrant was treated as a liability, and was recorded at a fair value of $7.6 million based upon the Black-Scholes valuation model and a closing price of Genta's common stock of $0.20 per share. The financing fee and the $7.6 million in deferred financing costs recorded upon the issuance of the warrant are being amortized over the two-year life of the not
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Genta Announces Second Quarter 2008 Financial Results and Conference Call
2. Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
3. Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
4. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
5. Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
6. Genta Announces Transfer of its Common Stock to the OTC Bulletin Board
7. Genta Announces Pending Transfer of its Common Stock to the Over-the-Counter Bulletin Board
8. Dr. Elizabeth Brown Joins Argenta TEC
9. Syngenta To Build Major Global Biotech Research Center in Beijing, China
10. Genta Restructures Operations to Focus on Priority Initiatives
11. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... RI (PRWEB) January 22, 2015 Protocol ... , The growing team of brand-neutral, independent consultants, Protocol ... Philip Rogers explained that over the years, his company ... , Moroso, Town of Plainfield, as well as others. ...
(Date:1/22/2015)... Madison, WI (PRWEB) January 22, 2015 Dr. ... at the 12th annual Scripps Natural Supplements Pre-Conference seminar on ... Supplements Conference is an annual continuing education conference for health ... 15th and included the topic of probiotics in health. Dr. ...
(Date:1/22/2015)... Jersey , 22 de enero de 2015  El Dr. ... hoy su llamada a nominaciones para 2015. Este prestigioso ... hecho, o tiene el potencial para hacer, contribuciones destacadas ... se aceptarán hasta el 15 de marzo de 2015 ...
(Date:1/22/2015)... 2015  Derma Sciences, Inc. (Nasdaq: DSCI ... wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic ... to the Premier, Inc. Regenerative Skin Grafting contract ... AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue to ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... Total acquisition price will be $215 million , ... for infectious disease , , CARLSBAD, ... (Nasdaq: ISIS ) and Abbott (NYSE: ABT ... the remaining equity ownership in Ibis Biosciences, Inc., an Isis subsidiary, ...
... ... (PRWEB) December 17, 2008 -- Facilitating the entry of ... analyzer, now updated to effortlessly examine not only the wireless interface ... but also the interface between the device CPU and the Bluetooth ...
... receives the AARC Zenith Award for Equipment and Service ... Anaheim , , IRVINE, ... ), the inventor of Pulse CO-Oximetry and Measure-Through-Motion and ... its remote monitoring and clinician notification system, Masimo Patient ...
Cached Biology Technology:Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis 2Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis 3Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis 4Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis 5Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 2Newly Available To Medical Device Manufacturers - Bluetooth Testing Equipment 3AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 2AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 3AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 4AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in 'Improving Patient Outcomes and Reducing Costs' in Post-Acute Care Facilities 5
(Date:12/22/2014)...  NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" ... growing mobile commerce market, announces it has retained famous pickpocket, ... 2015 International CES debut of the Wocket™ biometric smart wallet.  ... the NXT-ID booth January 6th and 7 th , 2015, ...
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., ... a study that pinpoints fine-scale differences in genetic ancestry of ... Since immigrants first arrived more than four hundred ... served as a meeting place for peoples from different continents. ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... New results presented at 3rd European Lung Cancer Conference ... improve the diagnosis and treatment of malignant pleural mesothelioma, ... lungs caused by asbestos exposure. Micro RNAs ... small molecule that is more abundant in the blood ...
... Lugano-CH/Aurora-US-CO/Geneva-CH, 18 April 2012 -- A new genetic signature ... and objective information about which patients with early stage ... relapse following surgery, investigators report at the 3rd European ... new avenues for immunotherapy for lung cancer. Non-small ...
... to increase loblolly pine production in the Southeast has improved ... climate change, according to a new study by North Carolina ... that grow faster and produce more wood, and what this ... environmental quality by scrubbing as much carbon out of the ...
Cached Biology News:Promising developments in early diagnosis and treatment of mesothelioma 2Promising developments in early diagnosis and treatment of mesothelioma 3Promising developments in early diagnosis and treatment of mesothelioma 4Gene signature helps identify risk of relapse in lung cancer patients 2
Peptide-affinity Purified Polyclonal Antibody to Sphingolipid Receptor Edg8/S1P5...
Peptide-affinity Purified Polyclonal Antibody to MAML1 / Mastermind Peptide with sequence VLPTCPMAEFALPR, from N Terminus of the protein sequence according to NP_055572....
DNA sequencing - plasmids or PCR fragments, 3-7 working days service....
LEAF™ Purified anti-human/mouse/rat ICOS...
Biology Products: